CXCR4与肿瘤的发生和发展
| 作者: |
1王峰,
1张声
1 福建医科大学附属第一医院病理科，福州 350005 |
| 通讯: |
张声
Email: zhgshg@126.com |
| DOI: | 10.3978/j.issn.2095-6959.2014.01.013 |
| 基金: | 福建医科大学第一临床学院学科带头人培养对象专项基金, JXK200724 |
摘要
趋化因子受体-4 (chemokine receptor-4，CXCR4)属趋化因子家族，为G蛋白偶联的7次跨膜受体蛋白，基质细胞衍生因子-12是该受体的唯一配体。目前发现CXCR4在23种不同类型肿瘤中均有表达，与肿瘤细胞的增殖、侵袭、转移及预后密切相关，针对CXCR4靶向治疗可望成为肿瘤基因治疗研究的新热点。
关键词：
趋化因子受体；肿瘤；CXCR4；CXCL12
Role of CXCR4 in the occurrence and development of tumors
CorrespondingAuthor: ZHANG Sheng Email: zhgshg@126.com
DOI: 10.3978/j.issn.2095-6959.2014.01.013
Abstract
The chemokine receptor-4 (CXCR4) belongs to the large super-family of G-protein-coupled seven-span transmembrane receptors and stromal derived factor-12 is the only known ligand for CXCR4. It has been shown that CXCR4 expresses in malignant cells from 23 different types of cancer and plays an important role in tumor proliferation, invasion, metastasis and prognosis. Targeted therapeutic approaches against CXCR4 might attract great attention in gene therapy for cancers.